BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 18973858)

  • 1. Two-dimensional imaging of tumour control probabilities and normal tissue complication probabilities.
    Szlag M; Slosarek K
    Rep Pract Oncol Radiother; 2010; 15(2):31-9. PubMed ID: 24376921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.
    Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK
    J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult.
    Ho KF; Fowler JF; Sykes AJ; Yap BK; Lee LW; Slevin NJ
    Acta Oncol; 2009; 48(3):431-9. PubMed ID: 18781445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convex reformulation of biologically-based multi-criteria intensity-modulated radiation therapy optimization including fractionation effects.
    Hoffmann AL; den Hertog D; Siem AY; Kaanders JH; Huizenga H
    Phys Med Biol; 2008 Nov; 53(22):6345-62. PubMed ID: 18941280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of traditional and simultaneous IMRT boost technique basing on therapeutic gain calculation.
    Slosarek K; Zajusz A; Szlag M
    Med Dosim; 2008; 33(4):299-302. PubMed ID: 18973858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review.
    Orlandi E; Palazzi M; Pignoli E; Fallai C; Giostra A; Olmi P
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):111-25. PubMed ID: 19409808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer.
    Grégoire V
    Rays; 2005; 30(2):105-8. PubMed ID: 16294902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling carcinogenesis after radiotherapy using Poisson statistics: implications for IMRT, protons and ions.
    Jones B
    J Radiol Prot; 2009 Jun; 29(2A):A143-57. PubMed ID: 19454805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiation therapy for head and neck carcinoma.
    Grégoire V; De Neve W; Eisbruch A; Lee N; Van den Weyngaert D; Van Gestel D
    Oncologist; 2007 May; 12(5):555-64. PubMed ID: 17522243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [IMRT and head and neck tumors: does differential fractionation have a role?].
    Giraud P; Servagi-Vernat S
    Cancer Radiother; 2013 Oct; 17(5-6):502-7. PubMed ID: 23969241
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.